Last reviewed · How we verify
NCT04800055
Attractive Targeted Sugar Bait Phase III Trial in Zambia
NA trial testing Attractive Targeted Sugar Bait in Malaria in 3,480 participants. Status unknown.
31 July 2023
Quick facts
| Lead sponsor | PATH |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 3,480 |
| Start date | 1 December 2020 |
| Primary completion | 31 July 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Zambia |
Drugs / interventions tested
- Attractive Targeted Sugar Bait
Conditions studied
- Malaria — all drugs for Malaria →
- Malaria,Falciparum — all drugs for Malaria,Falciparum →
- Vector-Borne Transmission of Infection — all drugs for Vector-Borne Transmission of Infection →
Sponsor
PATH — full company profile →
Who can join
Adults 12 Months to 15, any sex, with Malaria or Malaria,Falciparum. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The trial will evaluate the efficacy of ATSB deployment plus universal coverage of a WHO core vector control (VC) interventions over two transmission seasons on a minimum 30% reduction in cohort clinical disease incidence, confirmed case incidence, and parasite prevalence, as compared with VC alone. Measurement of entomological outcomes, assessment of acceptability and barriers to uptake and consistent use of ATSB, safety and adverse event monitoring and estimation of the cost and cost-effectiveness of ATSB will also occur.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Attractive targeted sugar bait phase III trials in Kenya, Mali, and Zambia.
Attractive Targeted Sugar Bait Phase III Trial Group. · · 2022 · cited 55× · PMID 35945599 · DOI 10.1186/s13063-022-06555-8 -
Entomological effects of attractive targeted sugar bait station deployment in Western Zambia: vector surveillance findings from a two-arm cluster randomized phase III trial.
Wagman J, Chanda B, Chanda J, Saili K, et al · · 2024 · cited 15× · PMID 39026236 · DOI 10.1186/s12936-024-05045-3 -
Efficacy of attractive targeted sugar bait stations against malaria in Western Province Zambia: epidemiological findings from a two-arm cluster randomized phase III trial.
Ashton RA, Saili K, Chishya C, Banda Yikona H, et al · · 2024 · cited 14× · PMID 39548456 · DOI 10.1186/s12936-024-05175-8 -
Residual bioefficacy of attractive targeted sugar bait stations targeting malaria vectors during seasonal deployment in Western Province of Zambia.
Mwaanga G, Ford J, Yukich J, Chanda B, et al · · 2024 · cited 8× · PMID 38811947 · DOI 10.1186/s12936-024-04990-3 -
Why does malaria transmission continue at high levels despite universal vector control? Quantifying persistent malaria transmission by Anopheles funestus in Western Province, Zambia.
Ashton RA, Chanda B, Chishya C, Muyabe R, et al · · 2024 · cited 7× · PMID 39402598 · DOI 10.1186/s13071-024-06457-5 -
Entomological Effects of Attractive Targeted Sugar Bait Station Deployment in Western Zambia: Vector Surveillance Findings from a Two-arm Cluster Randomized Phase III Trial
Wagman J, Chanda B, Chanda J, Saili K, et al · · 2024 · cited 1× · DOI 10.21203/rs.3.rs-4450785/v1 -
Cost and cost-effectiveness of attractive targeted sugar baits (ATSB) in the context of a phase III cluster randomized control trial in Western Province, Zambia.
Mancuso B, Orange E, Eisele TP, Ashton RA, et al · · 2025 · PMID 41420162 · DOI 10.1186/s12936-025-05716-9 -
Efficacy of Attractive Targeted Sugar Bait stations against malaria in Western Province Zambia: epidemiological findings from a two-arm cluster randomized Phase III trial
Ashton RA, Saili K, Chishya C, Yikona HB, et al · · 2024 · DOI 10.21203/rs.3.rs-5187530/v1
Verify or expand the search:
- PubMed search for NCT04800055
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Malaria
Currently open trials in the same condition.
- NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
- NCT07036159 — A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months · Phase 2 · recruiting
- NCT06735209 — First-in-Human PfSPZ-LARC2 Vaccination/CHMI · Phase 1 · active not recruiting
- NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants · Phase 1 · recruiting
- NCT06607003 — Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Cha · Phase 1 · recruiting
Other PATH trials
Trials by the same sponsor.
- NCT06895486 — Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation · Phase 2 · recruiting
- NCT06129916 — Assessing the Acceptability, Feasibility, Effectiveness and Cost-effectiveness of LADB · not yet recruiting
- NCT06879327 — Infant Malaria Vaccine Schedule Optimization · Phase 2 · recruiting
- NCT06137664 — Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines · Phase 1, PHASE2 · recruiting
- NCT05758506 — Developing a Screening Tool for Primary Immunodeficiency Disease (PID) in Pakistan · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04800055 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PATH
- Last refreshed: 18 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04800055.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing